N-substituted 2-(2, 5-dioxoimidazolidine-4-yl) acetamide compound as well as synthesis method and application of N-substituted 2-(2, 5-dioxoimidazolidine-4-yl) acetamide compound
The invention discloses an N-substituted 2-(2, 5-dioxoimidazolidine-4-yl) acetamide compound as well as a synthesis method and application thereof, and belongs to the technical field of tumor immunotherapy drug development. The N-substituted 2-(2, 5-dioxoimidazolidine-4-yl) acetamide compound disclosed by the invention is a small-molecule ITIM motif inhibitor, and the action mechanism of the N-substituted 2-(2, 5-dioxoimidazolidine-4-yl) acetamide compound is that the N-substituted 2-(2, 5-dioxoimidazolidine-4-yl) acetamide compound is combined with a tyrosine phosphorylated ITIM motif in a tumor cell membrane, so that the combination of the tyrosine phosphorylated ITIM and SH2 is blocked, SHP2 is always in an inhibition state, and meanwhile, the N-substituted 2-(2, 5-dioxoimidazolidine-4-yl) acetamide compound can be used for inhibiting tumor cells such as tumor cells such as PECAM-1, PD-1, a plurality of inhibitory receptor pathways such as CD3, SIRP alpha and the like are introduced, so that the anti-tumor activity of immune cells is finally improved. Experimental data show that the N-substituted 2-(2, 5-dioxoimidazolidine-4-yl) acetamide compound can effectively enhance killing of immune cells on tumor cells and inhibit growth of tumors, and application of the N-substituted 2-(2, 5-dioxoimidazolidine-4-yl) acetamide compound in tumor immunotherapy is fully supported..
| Medienart: |
|
|---|
Patent| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Europäisches Patentamt - (2023) vom: 12. Dez. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
ZHANG YINGQI [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Anmerkungen: |
Source: www.epo.org (no modifications made), First posted: 2023-12-12, Last update posted on www.tib.eu: 2024-03-13, Last updated: 2024-03-22 |
|---|
| Patentnummer: |
CN117209484 |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
EPA000484024 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | EPA000484024 | ||
| 003 | DE-627 | ||
| 005 | 20240322141909.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240315s2023 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)EPA000484024 | ||
| 035 | |a (EPA)CN117209484 | ||
| 035 | |a (EPA)89041706 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 0 | |a ZHANG YINGQI |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a N-substituted 2-(2, 5-dioxoimidazolidine-4-yl) acetamide compound as well as synthesis method and application of N-substituted 2-(2, 5-dioxoimidazolidine-4-yl) acetamide compound |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Source: www.epo.org (no modifications made), First posted: 2023-12-12, Last update posted on www.tib.eu: 2024-03-13, Last updated: 2024-03-22 | ||
| 520 | |a The invention discloses an N-substituted 2-(2, 5-dioxoimidazolidine-4-yl) acetamide compound as well as a synthesis method and application thereof, and belongs to the technical field of tumor immunotherapy drug development. The N-substituted 2-(2, 5-dioxoimidazolidine-4-yl) acetamide compound disclosed by the invention is a small-molecule ITIM motif inhibitor, and the action mechanism of the N-substituted 2-(2, 5-dioxoimidazolidine-4-yl) acetamide compound is that the N-substituted 2-(2, 5-dioxoimidazolidine-4-yl) acetamide compound is combined with a tyrosine phosphorylated ITIM motif in a tumor cell membrane, so that the combination of the tyrosine phosphorylated ITIM and SH2 is blocked, SHP2 is always in an inhibition state, and meanwhile, the N-substituted 2-(2, 5-dioxoimidazolidine-4-yl) acetamide compound can be used for inhibiting tumor cells such as tumor cells such as PECAM-1, PD-1, a plurality of inhibitory receptor pathways such as CD3, SIRP alpha and the like are introduced, so that the anti-tumor activity of immune cells is finally improved. Experimental data show that the N-substituted 2-(2, 5-dioxoimidazolidine-4-yl) acetamide compound can effectively enhance killing of immune cells on tumor cells and inhibit growth of tumors, and application of the N-substituted 2-(2, 5-dioxoimidazolidine-4-yl) acetamide compound in tumor immunotherapy is fully supported. | ||
| 650 | 4 | |a C07D: Heterocyclic compounds (macromolecular compounds c08) | |
| 650 | 4 | |a A61K: Preparations for medical, dental, or toilet purposes (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms a61j0003000000;chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles a61l; soap compositions c11d) | |
| 650 | 4 | |a A61P: Specific therapeutic activity of chemical compounds or medicinal preparations | |
| 650 | 4 | |a che | |
| 650 | 4 | |a 615 | |
| 700 | 0 | |a HE LEI |4 aut | |
| 700 | 0 | |a LI MENG |4 aut | |
| 700 | 0 | |a NIE HUIFANG |4 aut | |
| 700 | 0 | |a JIANG RU |4 aut | |
| 700 | 0 | |a WANG ZHAOWEI |4 aut | |
| 700 | 0 | |a GU JINTAO |4 aut | |
| 700 | 0 | |a DU HAICHEN |4 aut | |
| 700 | 0 | |a LI ZHAOZHAO |4 aut | |
| 700 | 0 | |a QIU YUEYUAN |4 aut | |
| 700 | 0 | |a SHI GEGE |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Europäisches Patentamt |g (2023) vom: 12. Dez. |
| 773 | 1 | 8 | |g year:2023 |g day:12 |g month:12 |
| 856 | 4 | 0 | |u https://worldwide.espacenet.com/patent/search/family/89041706/publication/CN117209484A1?q=CN117209484 |z kostenfrei |3 Volltext |
| 912 | |a GBV_EPA | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 12 |c 12 | ||